Abstract
Retinoic acid (RA) cures more than 75% of patients with acute promyelocytic leukemia (APL). Here, we review the various anti-cancer activities of retinoids and rexinoids, alone and in combination with other drugs, with emphasis on the RA-dependent induction of a cancer-cell-selective apoptosis signaling pathway to which multiple anti-cancer signals converge. These findings identify the TRAIL (tumor-necrosis-factor-related apoptosis-inducing ligand) pathway as a central cell-autonomous anti-cancer weapon that can act independently of the immune system.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Apoptosis / drug effects*
-
Apoptosis Regulatory Proteins
-
Epigenesis, Genetic
-
Humans
-
Leukemia, Promyelocytic, Acute / drug therapy*
-
Membrane Glycoproteins / metabolism
-
Models, Molecular
-
Receptors, Retinoic Acid / metabolism
-
Retinoids / pharmacology*
-
Retinoids / therapeutic use
-
TNF-Related Apoptosis-Inducing Ligand
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Apoptosis Regulatory Proteins
-
Membrane Glycoproteins
-
Receptors, Retinoic Acid
-
Retinoids
-
TNF-Related Apoptosis-Inducing Ligand
-
TNFSF10 protein, human
-
Tumor Necrosis Factor-alpha